
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova has demonstrated robust financial growth, with sales increasing by 29% to $803 million in 2024, highlighting strong market demand for its cardiopulmonary and neuromodulation solutions. The company's management has provided positive guidance, projecting sales to reach between $940 million and $955 million in the near term. Additionally, anticipated growth in the aura6000 device's market share, with revenue estimates ranging from $30 million to $280 million between 2027 and 2029, suggests significant future revenue potential for LivaNova.
Bears say
LivaNova is experiencing significant challenges, with projected revenue growth slowing to low-single digits primarily due to persistent headwinds in its Neuromodulation and Cardiovascular segments. Additionally, the company's operating margins are expected to contract, leading to earnings figures that are likely to fall below analyst consensus. Key risks further complicate the outlook, including potential delays in FDA approvals and slower growth in both Neuromodulation and Cardiopulmonary sectors, alongside anticipated margin improvement that may not materialize as expected.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares